Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes

• Published in: Journal of Immunology Research Vol. 2015; no. 2015; pp. 1 - 8
• Main Authors: Ambrožič, Aleš, Sodin-Semrl, Snezna, Božič, Borut, Kveder, Tanja, Tomšič, Matija, Perdan Pirkmajer, Katja, Žigon, Polona, Čučnik, Saša
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2015; Hindawi Limited; Wiley
• Subjects: Adult; Antibodies, Antiphospholipid - immunology; Anticoagulants; Antiphospholipid antibodies; Autoantibodies - immunology; beta 2-Glycoprotein I - immunology; Case-Control Studies; Classification; Confidence intervals; Female; Fetuses; Genetic aspects; Hemophilia; Humans; Immunoglobulin G - immunology; Immunoglobulin M - immunology; Immunology; Miscarriage; Obstetrics; Pathogenesis; Phosphatidylserines - immunology; Physiological aspects; Preeclampsia; Pregnancy; Pregnancy complications; Pregnancy Complications - diagnosis; Pregnancy Complications - epidemiology; Pregnancy Complications - immunology; Pregnancy Outcome; Prevalence; Prothrombin - immunology; Rheumatology; Risk factors; Studies; Thrombosis; Slovenia
• ISSN: 2314-8861; 2314-7156
• DOI: 10.1155/2015/975704

Objective. To determine the prevalence and clinical association of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in patients with a history of pregnancy complications relevant to antiphospholipid syndrome (APS). Materials and Methods. Two hundred and eleven patients with a history of (a) three or more consecutive miscarriages before 10th week of gestation (WG) (n=64), (b) death of a morphologically normal fetus beyond 10th WG (n=72), (c) premature birth of a morphologically normal neonate before 34th WG due to eclampsia, preeclamsia and placental insufficiency (n=33), and (d) less than three unexplained consecutive miscarriages before 10th WG (n=42). Subjects sera were analyzed for lupus anticoagulant (LA), anti-cardiolipin (aCL), anti-β2-glycoprotein I (anti-β2GPI), and aPS/PT antibodies. Results. 41/169 (24.3%) of patients were positive for at least one measured aPL. The highest prevalence was found for aPS/PT and aCL (13.0% and 12.4%, resp.) followed by LA (7.7%) and anti-β2GPI (7.1%). 11/169 with APS-related obstetric manifestations had only aPS/PT. 17.8% of patients were positive for LA or aCL and/or anti-β2GPI; however when adding the aPS/PT results, an additional 7% of patients could be evaluated for APS. Conclusion. aPS/PT are associated with recurrent early or late abortions and with premature delivery irrespective of other aPL.